<DOC>
	<DOCNO>NCT00507949</DOCNO>
	<brief_summary>The purpose trial study effect megestrol acetate gain body weight patient severe Chronic obstructive pulmonary disease order improve survival patient .</brief_summary>
	<brief_title>Study Evaluate Effect Megestrol Acetate Severe Chronic Obstructive Pulmonary Disease With Loss Weight</brief_title>
	<detailed_description>It demonstrate body weight measure Body mass index ( BMI ) independent risk factor mortality severe COPD.It seem one influence inflammatory factor development denutrition patient . The use especial diet good result aim improve weight , necessary complement muscular rehabilitation anabolic product . The megestrol acetate demonstrate good result short period time , nevertheless study scarce . The beneficial effect megestrol acetate seem mediate cytokine .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Clinical diagnose COPD ( criterion ATS/ERS 2004 ) Clinical stability 3 month Smokers exsmokers &gt; 10 boxes/year modify smoke habit study . FEV1 ( postbronchodilator ) &lt; 50 % . FEV1/FVC ≤ 70 Negative answer bronchodilator ( ≤ 20 % del FEV1 ≤ 200 ml.after 400 mcg.de salbutamol inhale ) BMI &lt; 21 Kg/m2 ó BMI 2125 Kg/m loss weight 5 % habitual body weight last 3 month , without reason could explain independently COPD . Use nasogastric catheter Concomitant treatment steroid , anabolics progestagens . Loss body weight related cause : hyperthyroidism , enteral malnutrition ( Crohn disease ... ) , neoplasias , etc Treatment Megestrol Acetate last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>COPD</keyword>
	<keyword>body weight</keyword>
	<keyword>megestrol acetate</keyword>
	<keyword>cytokine</keyword>
</DOC>